- 13-5699-80 - Invitrogen Antibodies MKI67 antibody

Submitted references Protein/AS01(B) vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors.

Nielsen CM, Ogbe A, Pedroza-Pacheco I, Doeleman SE, Chen Y, Silk SE, Barrett JR, Elias SC, Miura K, Diouf A, Bardelli M, Dabbs RA, Barfod L, Long CA, Haynes BF, Payne RO, Minassian AM, Bradley T, Draper SJ, Borrow P
Cell reports. Medicine 2021 Mar 16;2(3):100207

Functional Study of the Retrotransposon-Derived Human PEG10 Protease.

Golda M, Mótyán JA, Mahdi M, Tőzsér J
International journal of molecular sciences 2020 Mar 31;21(7)

Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.

Guedan S, Madar A, Casado-Medrano V, Shaw C, Wing A, Liu F, Young RM, June CH, Posey AD Jr
The Journal of clinical investigation 2020 Jun 1;130(6):3087-3097

Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.

Hara Y, Minami Y, Yoshimoto S, Hayashi N, Yamasaki A, Ueda S, Masuko K, Masuko T
Cancer medicine 2020 Jan;9(1):302-312

Human Liver Memory CD8(+) T Cells Use Autophagy for Tissue Residence.

Swadling L, Pallett LJ, Diniz MO, Baker JM, Amin OE, Stegmann KA, Burton AR, Schmidt NM, Jeffery-Smith A, Zakeri N, Suveizdyte K, Froghi F, Fusai G, Rosenberg WM, Davidson BR, Schurich A, Simon AK, Maini MK
Cell reports 2020 Jan 21;30(3):687-698.e6

Streptomyces Levis ABRIINW111 Inhibits SW480 Cells Growth by Apoptosis Induction.

Faramarzian Azimi Maragheh B, Fatourachi P, Mohammadi SM, Valipour B, Behtari M, Dehnad A, Nozad Charoudeh H
Advanced pharmaceutical bulletin 2018 Nov;8(4):675-682

Involvement of TWEAK and the NF-κB signaling pathway in lupus nephritis.

Sun F, Teng J, Yu P, Li W, Chang J, Xu H
Experimental and therapeutic medicine 2018 Mar;15(3):2611-2619

Small-Vessel Vasculopathy Due to Aberrant Autophagy in LAMP-2 Deficiency.

Nguyen HT, Noguchi S, Sugie K, Matsuo Y, Nguyen CTH, Koito H, Shiojima I, Nishino I, Tsukaguchi H
Scientific reports 2018 Feb 20;8(1):3326

Core Transcription Factors, MicroRNAs, and Small Molecules Drive Transdifferentiation of Human Fibroblasts Towards The Cardiac Cell Lineage.

Christoforou N, Chakraborty S, Kirkton RD, Adler AF, Addis RC, Leong KW
Scientific reports 2017 Jan 10;7:40285

S100A6 Regulates Endothelial Cell Cycle Progression by Attenuating Antiproliferative Signal Transducers and Activators of Transcription 1 Signaling.

Lerchenmüller C, Heißenberg J, Damilano F, Bezzeridis VJ, Krämer I, Bochaton-Piallat ML, Hirschberg K, Busch M, Katus HA, Peppel K, Rosenzweig A, Busch H, Boerries M, Most P
Arteriosclerosis, thrombosis, and vascular biology 2016 Sep;36(9):1854-67

Biliary tree stem cells, precursors to pancreatic committed progenitors: evidence for possible life-long pancreatic organogenesis.

Wang Y, Lanzoni G, Carpino G, Cui CB, Dominguez-Bendala J, Wauthier E, Cardinale V, Oikawa T, Pileggi A, Gerber D, Furth ME, Alvaro D, Gaudio E, Inverardi L, Reid LM
Stem cells (Dayton, Ohio) 2013 Sep;31(9):1966-79

Characteristics of CD8+ T cell subsets in Chinese patients with chronic HIV infection during initial ART.

Jiao Y, Hua W, Zhang T, Zhang Y, Ji Y, Zhang H, Wu H
AIDS research and therapy 2011 Mar 25;8:15

The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins.

Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J
The Journal of cell biology 1993 Nov;123(3):513-22

Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H
Journal of immunology (Baltimore, Md. : 1950) 1984 Oct;133(4):1710-5

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunocytochemistry of fixed and permeabilized HeLa cells stained with 5 µg/mL of Anti-Human Ki-67 Biotin followed by Streptavidin FITC (Product # 11-4317-87). Nuclei are stained with DAPI, colocalization appears aqua.
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Intracellular staining of 1-day Anti-Human CD3 Functional Grade Purified (Product # 16-0037-81)-stimulated normal human peripheral blood cells with Anti-Human CD19 APC (Product # 17-0198-42) and 0.06 µg of Anti-Human Ki-67 Biotin followed by Streptavidin PE (Product # 12-4317-87). Viable cells in the lymphocyte gate were used for analysis.
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Immunofluorescence characterization of transdifferentiated iCM (cardiac TF and microRNA). ( A ) Expression of ACTN2 and TNNT2 or ( B ) Expression of TNNT2 and Ki67 in HDF transdifferentiated for 2 weeks using induced expression of GATA4, TBX5, MEF2C, MYOCD, NKX2-5 and transfection with hsa-miR-1 and hsa-miR-133a. (Controls: M2rtTA only, microRNA only, cardiac TF only). ( C ) ACTN2. Panels on the right show varying degrees of cytoskeletal organization of ACTN2. ( D ) TNNT2. Panels on the right show varying degrees of cytoskeletal organization of TNNT2. ( E ) ACTN2 and GJA1. ( F ) TNNT2 and Ki67 expression in iCM. ( G ) VIM and MYH6/7. ( H ) TAGLN. ( I ) SMA. ( J ) MYH11. ( K ) ACTN2 expression in iCM 4 weeks following initiation of transdifferentiation. Panels on the right show varying degrees of cytoskeletal organization of ACTN2. ( L ) TNNT2 expression in iCM 4 weeks following initiation of transdifferentiation. Panels on the right show varying degrees of cytoskeletal organization of TNNT2.
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Determining the effect of small molecule inhibitors on transdifferentiation efficiency. ( A ) Immunofluorescence of transdifferentiated cells (ACTN2/TNNT2) during exposure to small molecule inhibitors: Janus protein tyrosine kinase 1 (JAK1i), Sodium Butyrate (HDACi), SB431542 (TGFbetai), CHIR99021 (GSK3i). ( B ) Number of nuclei, ( C ) Number of ACTN2 + cells, and ( D ) Number of TNNT2 + cells (per mm 2 ). ( E ) Number of Ki67 + nuclei normalized to the total number of nuclei. ( F ) Number of ACTN2 + cells normalized to the total number of nuclei. ( G ) Number of TNNT2 + cells normalized to the total number of nuclei. Experiment performed in triplicate. 4 images were analyzed for each experiment. Error bar represents calculated standard deviation. Significant difference between two values was calculated using t-test (two-tailed distribution, two sample unequal variance).
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 Determining the effect of protein ligands on transdifferentiation efficiency. ( A ) Immunofluorescence of transdifferentiated cells (ACTN2/TNNT2) during exposure to protein ligands: IGF1, EGF, NRG1, SDF1A. ( B ) Number of nuclei, ( C ) Number of ACTN2 + cells, and ( D ) Number of TNNT2 + cells (per mm 2 ). ( E ) Number of Ki67 + nuclei normalized to the total number of nuclei. ( F ) Number of ACTN2 + cells normalized to the total number of nuclei. ( G ) Number of TNNT2 + cells normalized to the total number of nuclei. Experiment performed in triplicate. 4 images were analyzed for each experiment. Error bar represents calculated standard deviation. Significant difference between two values was calculated using t-test (two-tailed distribution, two sample unequal variance).
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 12 PR PEG10 influences the proliferation of HEK293T cells. In the cell proliferation assay, HEK293T ( a ) and HaCaT cells ( b ) were stained with FITC-conjugated anti-Ki67 antibody, which was detected using a flow cytometer (FACS). Significance values were determined as compared to mock control, otherwise they are indicated. Note: * p 0.05). Error bars represent SD ( n >= 2).
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 High Autophagy Level of Intrahepatic T Cells Is Not a Result of a Difference in Differentiation Status or Recent Proliferation (A) Example plot of CD45RA versus CCR7 staining (CD8 + T cells) from a PBMC or IHL sample and summary data for LC3 staining of CD8 + T cell memory subsets (PBMC, 9; and IHL, 15, biological replicates; box whisker, Tukey). (B) Comparison of LC3 staining of CD8 + T cell memory subsets between paired PBMC and IHL samples (9 biological replicates; box whisker, Tukey; outliers shown as dots). (C) Ex vivo CD8 + T cell Ki67 expression. (D and E) Example plots (CD8 + T cells, PBMC) (D) and summary data for LC3 staining on Ki67 - and Ki67 + CD8 + T cells (E) in PBMCs and IHLs ex vivo (10 biological replicates) or after anti-CD3/CD28 stimulation (overnight, 0.5 mug/mL each; three biological replicates) in PBMCs. (F) Histograms showing the dilution of CellTrace Violet (CTV), LC3 staining, and co-staining of LC3 and CTV on CD8 + T cells after 5 days of stimulation with anti-CD3/CD28 (red), compared with that without stimulation (gray) or without CTV staining (black; two representative biological replicates of five, PBMCs). Cells were treated with bafA1 (A-F). Friedman test (ANOVA) with Dunn's post hoc test for pairwise multiple comparisons (A and B). Mann-Whitney t test (C and E). * p < 0.05, ** p < 0.005, *** p < 0.001.
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Streptomyces Levis ABRIINW111 can alter the apoptosis and proliferation of colon cancer cells. SW480 was treated with indicated concentrations of metabolites for 48 h and was evaluated by flow cytometry (FACS) for Caspase3 and Ki-67 expression. (a) FACS profile of Caspase 3 expression: Control cells (a) 100 ng ml -1 (b) 500 ng ml -1 (c) 1000 ng ml -1 (d).(b) Mean (SD) proportion of Caspase 3 expression with an indicated concentration of metabolites. (c) FACS profile of Ki67 expression: Control cells (a) 100 ng ml -1 (b) 500 ng ml -1 (c) 1000 ng ml -1 (d). (d) Mean (SD) proportion of Ki67 expression with the indicated concentrations of metabolites. Values are demonstrated as mean +- SD from 4 independent experiments (P_Value
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Anti-tumor effects of Ab3-8. Cells were injected subcutaneously into the left/right flanks of male nude mice. A, Time course of the in vivo anti-tumor study. B, Tumor volumes of CRC and HeLa cells were measured every 3 d using digital calipers, and were quantified using the formula: volume [mm 3 ] = (length [mm]) x (width [mm]) 2 x 0.5. Ab3-8 (100 mug/mouse) was intraperitoneally administered on days 1 and 9. Each dot represents the mean of 4-9 mice. Data are expressed as the mean +- SD. Tumor volume of individual mice shows in Figure S3 . C,Tumor sections from control mice were subjected to immunoperoxidase staining using Ab3-8. Scale bar, 20 mum. D, Tumor sections were subjected to immunoperoxidase staining using the indicated antibodies. Representative images of the SW1116- and HCT116-derived tumor sections, which immune labeled with p-AKT, p-ERK and Ki67. Images were obtained at 4 x magnification. Scale bar, 20 mum. Insets, higher magnification of the boxes. Images were obtained at 20 x magnification. Scale bar, 20 mum
Conjugate: Biotin

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 PfRH5 vaccination with the ChAd63-MVA platform induces greater activation of total circulating CD8 + and CD4 + T cell populations, while the protein/AS01 B platform elicits a more sustained increase in cTfh-phenotype cells PBMCs from days 0, 7, 14, and 63 were stained ex vivo and analyzed using the gating strategies shown in Figures S1-S3 . (A and B) Increases at day 63 in activated CD38 + Ki67 + cells within total CD8 + and CD4 + T cells (A) or Th1 (CXCR3 + CCR6 - ), Th2 (CXCR3 - CCR6 - ), and Th17 (CXCR3 - CCR6 + ) CD4 + T cell subsets (B) were compared between platforms following subtraction of day 0 CD38 + Ki67 + frequencies in paired samples. (C-E) Frequencies of total cTfh cells defined as CXCR5 + (C) or CXCR5 + PD1 + (D) cells within the CD45RA - CD4 + T cell population were compared between platforms and the frequency of cTfr cells within total cTfh cells (defined as the CD25 + Foxp3 + subset) (E). All of the available samples are plotted (ChAd63-MVA/protein/AS01 B ): day 0, n = 15/54; day 7, n = 15/24; day 14, n = 15/54; day 63, n = 12/20. For intra-trial comparisons (E), only vaccinees with all 4 time points were analyzed: ChAd63-MVA, n = 12, protein/AS01 B , n = 17. Comparisons were performed with Mann-Whitney tests (between trials) or Friedman tests with Dunn's correction for multiple comparisons (within trials comparing day 0 to post-vaccination time points). *p < 0.5, **p < 0.01, and ***p < 0.001. In all of the panels, each point represents a vaccinee.
Conjugate: Biotin

13-5699-80

Antibody data